Is it safe to start an ACE inhibitor (angiotensin‑converting enzyme inhibitor) or angiotensin‑II receptor blocker and an SGLT2 inhibitor (dapagliflozin) in a patient with chronic kidney disease stage 3?

No, it is NOT bad—it is strongly recommended and evidence-based practice.

Starting both an ACE inhibitor (or ARB) and an SGLT2 inhibitor like dapagliflozin in a patient with CKD stage 3 is the current standard of care and should be done in most cases. The 2024 KDIGO guidelines provide the highest level of evidence (1A recommendation) for both medication classes in this population 1.

Why This Combination is Recommended

ACE Inhibitor/ARB in CKD Stage 3

• Strongly recommended for patients with CKD and albuminuria (either moderate A2 or severe A3), regardless of diabetes status 1
• Continue ACE inhibitor/ARB even when eGFR falls below 30 mL/min/1.73 m² (which is CKD stage 4) 1
• Use the highest approved tolerated dose to achieve maximum benefit 1

SGLT2 Inhibitor (Dapagliflozin) in CKD Stage 3

• 1A recommendation (strongest evidence level) for adults with CKD and eGFR ≥20 mL/min/1.73 m² when:
  • Urine albumin-to-creatinine ratio ≥200 mg/g, OR
  • Heart failure is present, OR
  • Type 2 diabetes is present 1
• 2B recommendation even for those with eGFR 20-45 mL/min/1.73 m² and lower albuminuria (<200 mg/g) 1

Practical Implementation Algorithm

Step 1: Confirm Appropriateness

• Check baseline eGFR (should be ≥20 mL/min/1.73 m²)
• Check baseline potassium (should be ≤5.5 mmol/L for safe initiation)
• Verify patient is not in acute illness, prolonged fasting, or perioperative state 1

Step 2: Initiate Both Medications

You can start both simultaneously in stable CKD stage 3 patients. There is no requirement to stagger them.

For ACE inhibitor/ARB:

• Start at standard dose and titrate to maximum tolerated dose
• Check creatinine and potassium in 2-4 weeks 1

For dapagliflozin:

• Standard dose: 10 mg daily (no dose adjustment needed for CKD stage 3) 2
• SGLT2i initiation does not require more frequent monitoring than usual CKD care 1

Step 3: Monitoring After Initiation

Within 2-4 weeks of ACE inhibitor/ARB start:

• Serum creatinine: Accept up to 30% rise from baseline—this is expected and not a reason to stop 1
• Potassium: If rises to 5.5-5.9 mmol/L, manage medically (dietary restriction, diuretics, potassium binders) rather than stopping the ACE inhibitor 1

For dapagliflozin:

• The reversible eGFR dip after starting is expected and not an indication to stop 1
• Continue routine CKD monitoring schedule (no need for extra visits) 1

Critical Safety Considerations

When to STOP or HOLD ACE Inhibitor/ARB:

• Creatinine rises >30% within 4 weeks 1
• Symptomatic hypotension despite management
• Uncontrolled hyperkalemia (>6.0 mmol/L) despite medical treatment 1

When to HOLD Dapagliflozin Temporarily:

• Prolonged fasting, surgery, or critical illness (ketoacidosis risk) 1, 2
• Active urinary tract infection or genital mycotic infection (treat infection first) 2

When to STOP Dapagliflozin:

• Kidney replacement therapy is initiated 1
• Intolerable side effects (rare)

Common Pitfalls to Avoid

1. Don't stop ACE inhibitor for small creatinine rises (<30%): This is hemodynamic and expected, not kidney injury 1

2. Don't stop ACE inhibitor for mild hyperkalemia (5.5-5.9 mmol/L): Use potassium management strategies first 1

3. Don't withhold SGLT2i due to eGFR concerns in stage 3: Evidence supports use down to eGFR 20 mL/min/1.73 m² 1

4. Don't delay starting both medications: The combination provides additive kidney and cardiovascular protection 3, 4

5. Don't stop dapagliflozin for the initial eGFR dip: This is a known hemodynamic effect that reverses and doesn't indicate harm 1

Evidence Strength

The recommendation to use both medications is based on:

• Multiple large randomized trials showing mortality and kidney failure reduction 5, 4
• DAPA-CKD trial specifically demonstrated 39% reduction in kidney disease progression, 29% reduction in cardiovascular events, and 31% reduction in all-cause death in CKD patients 4
• Benefits were consistent regardless of diabetes status 1, 4
• Safety profile in CKD stage 3 is well-established and manageable 2, 6

The combination of ACE inhibitor/ARB plus SGLT2 inhibitor represents the most effective kidney-protective strategy currently available and should be standard practice for appropriate CKD stage 3 patients.